NCT01050413

Brief Summary

This study aimed to evaluate serum thymidine kinase 1 (TK1) activity as a marker for solid tumors and more specifically in: preoperative testing for prediction of disease recurrence and survival; follow-up after surgical removal of the original tumor for early detection of disease recurrence and in monitoring therapy as a surrogate marker of tumor response.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
300

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Feb 2010

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 5, 2010

Completed
10 days until next milestone

First Posted

Study publicly available on registry

January 15, 2010

Completed
17 days until next milestone

Study Start

First participant enrolled

February 1, 2010

Completed
10 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2010

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2011

Completed
Last Updated

June 3, 2010

Status Verified

December 1, 2009

Enrollment Period

10 months

First QC Date

January 5, 2010

Last Update Submit

June 2, 2010

Conditions

Solid Tumors

Keywords

Thymidine Kinase 1 activitydiagnosisprognosisfollow-up

Study Arms (1)

1

colon cancer, prostate cancer, lung cancer, ovarian cancer

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

patients from oncology department and patients visiting outpatient, daycare oncology clinic

You may qualify if:

  • patients with colon, breast, prostate and lung cancer before and during treatment

You may not qualify if:

  • pregnant women;
  • patients with generalized CMV and HZV infections;
  • patients with severe rheumatoid arthritis

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Hadassah Medical Organization

Jerusalem, Israel

RECRUITING

Biospecimen

Retention: SAMPLES WITHOUT DNA

Serum

MeSH Terms

Conditions

Disease

Condition Hierarchy (Ancestors)

Pathologic ProcessesPathological Conditions, Signs and Symptoms

Central Study Contacts

Tamar Peretz, MD

CONTACT

6777825tamary@hadassah.org.il

Hadas Lemberg, PhD

CONTACT

6777572lhadas@hadassah.org.il

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER

Study Record Dates

First Submitted

January 5, 2010

First Posted

January 15, 2010

Study Start

February 1, 2010

Primary Completion

December 1, 2010

Study Completion

December 1, 2011

Last Updated

June 3, 2010

Record last verified: 2009-12

Locations

IL(1)